secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000320017-23-000027
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Q1 net loss $6.2M; cash $61.1M; LSTA1 advances but LSTA201 disappoints
-----------------------------------------------------------------------------

- Q1 net loss $6.2M vs $4.2M YoY; R&D $3.2M, G&A $3.7M.
- Cash, equivalents & marketable securities $61.1M as of Mar 31; plus $2.2M non-dilutive NJ tax credit received Q2.
- LSTA1: first patient dosed in iLSTA trial for pancreatic cancer; basket trial in solid tumors planned before end of Q2 2023.
- LSTA201 for diabetic kidney disease showed safety but no consistent kidney function improvement; development only with partner.
- HONEDRA (LSTA12) for critical limb ischemia in Japan: pre-consultation with PMDA; seeking partner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001723000027/0000320017-23-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001723000027/clbs-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000320017-23-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer